PepGen Inc
PEPG4.480USD
+0.190+4.43%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
307.99MCap. mercado
PérdidaP/E TTM
Más Datos de PepGen Inc Compañía
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Información de PepGen Inc
Símbolo de cotizaciónPEPG
Nombre de la empresaPepGen Inc
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoMcArthur (James G)
Número de empleados81
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 06
Dirección245 Main St, 2nd Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono17034568000
Sitio Webhttps://pepgen.com
Símbolo de cotizaciónPEPG
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoMcArthur (James G)
Ejecutivos de PepGen Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+51500.00%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Dr. Mitchell Finer
Dr. Mitchell Finer
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+51500.00%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Commodore Capital LP
3.43%
Vivo Capital, LLC
3.38%
Otro
51.73%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Commodore Capital LP
3.43%
Vivo Capital, LLC
3.38%
Otro
51.73%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
40.87%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
15.94%
Investment Advisor
8.07%
Sovereign Wealth Fund
1.81%
Private Equity
1.21%
Research Firm
0.85%
Individual Investor
0.18%
Otro
6.41%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
181
64.21M
93.39%
+29.65M
2025Q3
157
41.73M
60.71%
+1.86M
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
20.06M
29.19%
+9.38M
+87.70%
Sep 30, 2025
Oxford Science Enterprises PLC
4.96M
7.21%
+200.00K
+4.21%
Sep 30, 2025
Viking Global Investors LP
3.48M
5.07%
+2.00M
+134.91%
Sep 30, 2025
Commodore Capital LP
2.36M
3.43%
+2.36M
--
Sep 30, 2025
Vivo Capital, LLC
2.33M
3.38%
+2.33M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.77M
2.57%
+831.33K
+88.72%
Sep 30, 2025
Point72 Asset Management, L.P.
2.03M
2.95%
-729.17K
-26.43%
Sep 30, 2025
BVF Partners L.P.
1.92M
2.79%
+1.92M
--
Sep 30, 2025
Laurion Capital Management LP
1.89M
2.75%
+1.08M
+133.38%
Sep 30, 2025
RTW Investments L.P.
1.50M
2.18%
+1.50M
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Ver más
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
iShares Micro-Cap ETF
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
